Patents by Inventor John R. Butler

John R. Butler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS
    Publication number: 20240124442
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 18, 2024
    Applicant: AMGEN INC.
    Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Kevin Lloyd GREENMAN, Todd J. KOHN, Kexue LI, Qingyian LIU, Ana Elena MINATTI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Hui-Ling WANG, Nicholas Anthony WEIRES
  • TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS
    Publication number: 20240101570
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).
    Type: Application
    Filed: November 22, 2021
    Publication date: March 28, 2024
    Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Francesco MANONI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Nuria A. TAMAYO, Mikkel VESTERGAARD, Hui-Ling WANG, Nicholas Anthony WEIRES
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20240092794
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 21, 2024
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • PRMT5 inhibitors
    Patent number: 11845760
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: December 19, 2023
    Assignee: AMGEN INC.
    Inventors: Shon Booker, Matthew Paul Bourbeau, John R. Butler, Sanne Ormholt Schroder Glad, Brian Alan Lanman, Patricia Lopez, Francesco Manoni, Liping H. Pettus, Ian Sarvary, Nuria A. Tamayo, Mikkel Vestergaard, Nicholas Anthony Weires
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • N-cyano-7-azanorbornane derivatives and uses thereof
    Patent number: 11572374
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventors: John R. Butler, Daniel Erlanson, Russell Graceffa, Jeffrey Iwig, Joon Won Jeong, Ryan D. White, Yongwei Wu, Shuyan Yi, Xiao Mei Zheng, Jesse M. McFarland, Abhisek Banerjee
  • N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF
    Publication number: 20220363694
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 17, 2022
    Applicants: Amgen Inc., Carmot Therapeutics, Inc.
    Inventors: John R. BUTLER, Daniel ERLANSON, Russell GRACEFFA, Jeffrey IWIG, Joon Won JEONG, Ryan D. WHITE, Yongwei WU, Shuyan YI, Xiao Mei ZHENG, Jesse M. MCFARLAND, Abhisek BANERJEE
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20220194955
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • COUPON AND CONTEST BUSINESS METHODS
    Publication number: 20200250695
    Abstract: A coupon and/or contest business method is described. Users can be given the opportunity to obtain and use a coupon that provides benefits such as discounts at a multitude of different stores. The users can also be entered into one or more contests. For instance, in one embodiment, the user is automatically entered into a first contest via use of the coupon, and can enter a second contest for a nominal fee, such as a fee of $0.25 /month. Periodic prizes, such as monthly giveaways, can be included.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Inventor: John R. Butler
  • Pyridine sulfonamides
    Patent number: 10668067
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, John R. Butler, Benjamin Charles Milgram, Gwenaella Rescourio, Alessandro Boezio, Brian Andrew Sparling, Daniel La
  • PYRIDINE SULFONAMIDES
    Publication number: 20190167682
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: July 20, 2017
    Publication date: June 6, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, John R. BUTLER, Benjamin Charles MILGRAM, Gwenaella RESCOURIO, Alessandro BOEZIO, Brian Andrew SPARLING, Daniel LA
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9458152
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: October 4, 2016
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgram, Hanh Nho Nguyen, Emily Anne Peterson, Karina R. Vaida, Brian Sparling
  • BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
    Publication number: 20160046626
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 18, 2016
    Inventors: Matthew WEISS, Alessandro BOEZIO, Christiane BOEZIO, John R. BUTLER, Margaret Yuhua CHU-MOYER, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Daniel LA, Isaac E. MARX, Benjamin Charles MILGRAM, Hanh Nho NGUYEN, Emily Anne PETERSON, Karina R. VAIDA, Brian SPARLING
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9212182
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgrim, Hanh Nho Nguyen, Emily Peterson, Karina Romero, Brian Sparling
  • BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
    Publication number: 20140371201
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: June 11, 2014
    Publication date: December 18, 2014
    Inventors: Matthew WEISS, Alessandro BOEZIO, Christiane BOEZIO, John R. BUTLER, Margaret Yuhua CHU-MOYER, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Daniel LA, Isaac E. MARX, Benjamin Charles MILGRIM, Hanh Nho NGUYEN, Emily PETERSON, Karina ROMERO, Brian SPARLING
  • Penetrator interface adapter concept
    Patent number: 4434927
    Abstract: A penetrator interface adapter comprising a generally cylindrical fluted oilless nozzle adapter with means for positioning a penetrator with holder and an energy absorbing collar adjacent the target container so that the penetrator projects into the target or into the container to a predetermined point during each shot.
    Type: Grant
    Filed: June 24, 1981
    Date of Patent: March 6, 1984
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: John R. Butler, Gerald D. Shock, Norman J. Saunders
  • Magnetron filter
    Patent number: 4006382
    Abstract: A harmonic frequency suppressor is disclosed for microwave magnetrons having an output antenna probe member. A coaxial cylindrical member is disposed within the vacuum envelope to provide in combination with the antenna probe member a line filter for suppressing harmonic frequencies of the generated output signal frequency. The length of the coaxial member is dimensioned to suppress the desired harmonic frequency.
    Type: Grant
    Filed: September 24, 1975
    Date of Patent: February 1, 1977
    Assignee: Raytheon Company
    Inventors: John R. Butler, Patricia M. Scott